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ARTICLE

Tisagenlecleucel Model-Based Cellular Kinetic Analysis of
Chimeric Antigen Receptor–T Cells
Andrew M. Stein1,*, Stephan A. Grupp2,3, John E. Levine4,5, Theodore W. Laetsch6,7, Michael A. Pulsipher8, Michael W. Boyer9,
, Bruce L. Levine11,12, Lori Tomassian13, Sweta Shah13, Mimi Leung13, Pai-Hsi Huang13, Rakesh Awasthi14,
Keith J. August10
Karen Thudium Mueller14, Patricia A. Wood13 and Carl H. June11,12

Tisagenlecleucel is a chimeric antigen receptor–T cell therapy that facilitates the killing of CD19+ B cells. A model was developed for the kinetics of tisagenlecleucel and the impact of therapies for treating cytokine release syndrome (tocilizumab
and corticosteroids) on expansion. Data from two phase II studies in pediatric and young adult relapsed/refractory B cell
acute lymphoblastic leukemia were pooled to evaluate this model and evaluate extrinsic and intrinsic factors that may impact
the extent of tisagenlecleucel expansion. The doubling time, initial decline half-life, and terminal half-life for tisagenlecleucel
were 0.78, 4.3, and 220 days, respectively. No impact of tocilizumab or corticosteroids on the expansion rate was observed.
This work represents the first mixed-effect model-based analysis of chimeric antigen receptor–T cell therapy and may be
clinically impactful as future studies examine prophylactic interventions in patients at risk of higher grade cytokine release
syndrome and the effects of these interventions on chimeric antigen receptor–T cell expansion.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
✔ Tisagenlecleucel is a chimeric antigen receptor (CAR)–T
cell therapy that facilitates the targeted cell killing of CD19+ B
cells and provides robust responses in acute lymphoblastic
leukemia and diffuse large B cell lymphoma. However, comprehensive cellular models that describe CAR-T cell kinetics
are lacking.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ A model-based analysis was used to characterize the
kinetics of tisagenlecleucel therapy and to assess the
impact on expansion of intrinsic and extrinsic factors, with
Chimeric antigen receptor (CAR)–T cell therapy involves the
adoptive transfer of autologous T cells genetically modified
to facilitate antigen-specific cell killing through endogenous
effector cell mechanisms of cytotoxicity.1 Unlike canonical
drug therapies that can be described by classical pharmacokinetics (PK), CAR-T cells undergo rapid expansion
several logs beyond the infused cell dose and demonstrate
long-term persistence that does not follow typical models
1

a focus on comedications for treating cytokine release
syndrome (tocilizumab and corticosteroids).
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔ This work represents the first mixed-effect model-based
analysis of CAR-T cell therapy. No impact of tocilizumab or
corticosteodis on the expansion rate was observed.
HOW MIGHT THIS CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS?
✔ This work provides a methodology for future studies in
patients at risk of severe adverse events for assessing the
impact of earlier anti–cytokine release syndrome therapy,
which may impede CAR-T cell kinetics or efficacy.
of metabolism and clearance. Characterization of the cellular kinetics of CAR-T cells as well as factors impacting kinetics are important for understanding the efficacy, safety,
and recommended dose ranges.
Tisagenlecleucel (CTL019) is a CAR-
T cell immunotherapy that produces durable responses in pediatric and
young adult patients with relapsed or refractory B cell
acute lymphoblastic leukemia (r/r B-ALL).2,3 This treatment
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paradigm genetically modifies autologous T cells to express a bioengineered CAR that will facilitate the targeted
killing of CD19+ B cells. Following infusion, widespread
distribution of tisagenlecleucel into various tissues occurs within a few hours.4 During the next several days,
increases in the tisagenlecleucel copy number reflect
exponential growth, whereby tisagenlecleucel binding to
its target antigen induces the killing of the target cell and
stimulates proliferation of the CAR-T cells. After the time
of maximal expansion (Tmax) is reached, the kinetics of tisagenlecleucel expansion are followed by a biexponential
decline. The initial contraction occurs at a rapid rate and is
thought to correspond to programmed cell death of activated CAR-T cells.5 The second phase of tisagenlecleucel
decline occurs more gradually over time and corresponds
to the persistence of CAR-T cells that demonstrate an immune memory phenotype.6
The initial distribution of tisagenlecleucel after the administered cell dose depends largely on the complex interplay
between T-cell trafficking, migration from peripheral blood
to the bone marrow and other secondary lymphoid tissues,
and the immune activation of tisagenlecleucel through binding of CD19 antigen on the surface of B cells. This unique
pharmacology, including an initial characterization of the
kinetics of tisagenlecleucel expansion, has previously been
reported in single-
center studies that included pediatric
and adult patients with r/r B-ALL and patients with chronic
lymphocytic leukemia.7 The results from these prior studies
demonstrated (i) higher expansion of tisagenlecleucel in peripheral blood in responding patients than in nonresponding patients, (ii) higher grades of cytokine release syndrome
(CRS) in patients with higher baseline tumor burden and
greater expansion,7 and (iii) the significance of long-term tisagenlecleucel expansion and persistence in producing durable responses in patients with chronic lymphocytic leukemia
and those with acute lymphoblastic leukemia.
Cytokine release syndrome typically occurs within
1–22 days of tisagenlecleucel infusion and is an on-target
toxicity that results from tisagenlecleucel activation, expansion, and tumor-cell killing.3 Because CRS is an on-target
effect, CRS and efficacy are correlated. CRS is associated
with increased serum levels of proinflammatory cytokines,
including interleukin (IL)-6.1 Although CRS has been successfully managed in some pediatric and young adult patients with r/r B-ALL using supportive care, patients with
severe CRS have shown benefit from tocilizumab (anti–IL-6
receptor antibody) treatment and in some instances treatment with corticosteroids to further control CRS symptoms. Tocilizumab has been approved by the US Food and
Drug Administration for treating CRS and among patients
receiving tisagenlecleucel or axicabtagene ciloleucel, and
it was observed that 69% of patients were responders.8
There is a potential for these comedications to impact the
CAR-T cells because corticosteroids are known to reduce
circulating T cells9 and induce apoptosis,10 and tocilizumab is an anti-inflammatory medication that could also
potentially impact T cells. Mueller and colleagues7 previously reported that tisagenlecleucel continues to expand
and persist following the administration of tocilizumab and/
or steroids in patients experiencing severe CRS; however,
CPT: Pharmacometrics & Systems Pharmacology

model-based methods characterizing the impact of tocilizumab on tisagenlecleucel expansion have not been previously described. A model-based approach allowed us to
assess whether anti-inflammatory therapy would alter the
expansion profile of the patient who receives it.
In this analysis, a nonlinear, mixed-effects modeling approach was used to characterize the impact of tocilizumab
therapy on the kinetics of in vivo tisagenlecleucel expansion.
The primary focus of this work was to investigate the differences in peak tisagenlecleucel levels and the rates of tisagenlecleucel expansion in patients who underwent tocilizumab
or corticosteroid therapy when compared with patients who
did not require these treatments for CRS to assess whether
anti-inflammatory therapy would alter the tisagenlecleucel
expansion profile in the patients who receive it.
METHODS
Data
Data from two phase II studies of pediatric and young
adult B-ALL (NCT02435849 (ELIANA) and NCT02228096
(ENSIGN)) were used for this analysis. ELIANA is an ongoing global trial that included 62 patients from 10 countries
at the time of data cutoff, August 17, 2016. ENSIGN is a US
multicenter trial that enrolled a total of 29 patients at the
time of data cutoff, February 1, 2016. Both clinical studies
have near-identical enrollment and treatment protocols, allowing data to be pooled for analyses. The patients received
a single dose of tisagenlecleucel. The median weight-
adjusted dose was 3.1 × 106 CAR-positive viable T cells
per kg (range, 0.2–5.4 × 106 cells/kg) for patients weighing
≤50 kg, and the median total dose of CAR-positive viable T
cells was 1.0 × 108 (range, 0.03–2.6 × 108 cells) for patients
weighing > 50 kg. The patient outcomes from interim analyses have been previously reported.2,11
Both studies were approved by the institutional review
boards at each participating institution and conducted in
accordance with the Declaration of Helsinki. ELIANA was
sponsored and designed by Novartis Pharmaceuticals
Corporation and ENSIGN was designed by the University
of Pennsylvania and sponsored in conjunction with Novartis
Pharmaceuticals Corporation. The patients or their guardians provided written informed consent or assent.
Sample analysis
Tisagenlecleucel levels, reported as transgene copies/μg
of genomic DNA, were measured in 90 patients (ELIANA,
N = 61; ENSIGN, N = 29) using quantitative polymerase
chain reaction (qPCR). Briefly, genomic DNA was isolated
from samples of peripheral blood, and transgene copies were quantified using TaqMan technology (Applied
Biosystems, Foster City, CA) and transgene-specific primers. A validated assay was used to detect integrated transgene sequences.7,12 To ensure quality control, a parallel
amplification reaction was performed using a primer-probe
combination specific to a nontranscribed sequence upstream of the cyclin-dependent kinase inhibitor 1A gene,
p21, CDKN1A.6 Amplification of the reference sequence was
used to normalize the absolute quantification of the CD19
CAR transgene. The limit of quantification was 10 copies per
reaction (≈ 50 transgene copies per μg of genomic DNA).
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The above model equations are empirical in nature and
describe the available data. The equations above are also
described by the semimechanistic compartmental model in
Figure 2.4 Effector CAR-T cells can expand exponentially
(ρ) up until time Tmax and then decline (α − k) or transition to
memory cells (k) such that the total rate constant for the decline of this population at time Tmax is α, which then persist
and decline with a rate constant β.6 The analytical solution
to this compartmental model gives rise to Eq. 1 describing the PK of tisagenlecleucel (Supplementary Material).
Other semimechanistic models can also give rise to similar
kinetics, as described in the Discussion section.
Comedication effect on expansion. As mentioned
previously, CRS is an on-
target toxicity associated with
tisagenlecleucel activation and cellular expansion and in

Expansion (ρ)

100,000

Tisagenlecleucel Transgene
(copies/µg)

Model-based analysis of tisagenlecleucel
Base model. The base structural model is adapted from a
previously published empirical model used to describe the
murine immune responses to Listeria monocytogenes or
lymphocytic choriomeningitis virus, in which similar profiles
of lymphocyte kinetics were observed; we use the analytical
solution to equation 7 from DeBoer and Perelson.4 The
structural model captures the exponential expansion of
tisagenlecleucel with rate constant ρ up to time Tmax, followed
by biexponential contraction after Tmax with rate constants
α and β. The α slope corresponds to a rapid contraction as
a result of the programmed apoptosis of most activated
lymphocytes following the initial immune response, and
the β slope corresponds to a gradual decrease of T cells
that can persist in the body for years or even decades.13–15
A typical model profile is shown in Figure 1a. The model
has the following six fixed parameters: Cmax, Tmax, fold x,
FB, α, and β. Cmax is the maximum transgene copies of
tisagenlecleucel that occurs at time Tmax; fold x is the fold
expansion of tisagenlecleucel from baseline and is given by
fold x = exp(ρ·Tmax), where ρ = log(fold x)/Tmax. FB describes
the fraction of transgene copies present at peak expansion
(Tmax), which decline with gradual rate constant β, and
(1 − FB) is the fraction of transgene copies present at peak
expansion, which decline with the rapid rate constant α.
For the base model, the terms R0, A, and B in the equations
were computed as follows to ensure continuity: R0 = Cmax/
foldx, R0 is the baseline transcript levels in Eq. 1; A = Cmax
(1 − FB); B = Cmax·FB. A and B correspond to a portion of Cmax
that declines rapidly (at slope α) and more gradually (at slope
β) at time Tmax. These parameters were employed in Eq. 1.
{
R0 eρt ,
t < Tmax
(1)
f (t) =
Ae−α(t−Tmax ) + Be−𝛽(t−Tmax ) , t ≥ Tmax

(a)

Contraction (α)
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The samples were collected at days 1, 2, 7, 11, 14, 21, and
28 and followed by 3-month intervals from months 3–12 and
then 6-month intervals until month 60. Day 1 corresponded
to the day of infusion or first dose of tisagenlecleucel. In this
study, tisagenlecleucel levels were also measured by flow
cytometry. Good correlation between flow cytometry and
qPCR was observed, and qPCR was selected for this analysis because it was a more sensitive assay,7 allowing for
better characterization of long-term persistence.

10,000
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Figure 1 Graphical representation of the cellular kinetic models.
(a) The graph depicts the mathematical model of tisagenlecleucel
following expansion at a rate (ρ) up to time to maximal expansion
(Tmax), followed by a biphasic contraction at rates α and β.
Because FB is much <1, the initial decline rate is well estimated
by α. (b) Mathematical model for tisagenlecleucel expansion
concurrent with tocilizumab and corticosteroid administration
given at times Ttoci and Tster, respectively. The model allows for a
reduced rate of expansion with Fster, effect of steroids, and Ftoci,
effect of tocilizumab. FB, fraction of transgene copies present
during the decline at the gradual rate β, starting from Tmax;
Fster, effect of steroids; Ftoci, effect of tocilizumab; Tster, time to
maximal expansion with steroid therapy; Ttoci, time to maximal
expansion with tocilizumab therapy.

some cases requires the use of tocilizumab or corticosteroids
to ameliorate severe symptoms and mitigate inflammatory
organ damage. The key objective of this analysis was to
study the impact of tocilizumab and corticosteroids on
tisagenlecleucel expansion as used per the treatment
algorithm16 outlined in the study protocol. The following two
relationships between expansion and the comedications for
treating CRS were explored: (i) treatment with tocilizumab
and/or corticosteroids may slow the rate of expansion
of tisagenlecleucel, and (ii) the requirement of treatment
for CRS may be predictive of Cmax because patients with
www.psp-journal.com
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Compartmental model

Figure 2 Compartmental model describing T-cell kinetics. The model has exponential growth of effector cells (E) at rate ρ before time to
maximal expansion (Tmax). After Tmax, effector cells rapidly decline at rate (α-k) and convert to memory cells at rate k; the memory cells then
decline at a rate β. The rapid decline is most likely caused by programmed cell death following immune activation, and a slower decline rate
is indicative of a longer persistence of the memory effector T-cell phenotype. The equations describing the rates of expansion and decline
are shown. Additional information about the model can also be found in the Supplementary Material. Cmax, maximal concentration; FB,
fraction of transgene copies present during the decline at the gradual rate β, starting from Tmax; foldx, fold expansion; Fster, effect of steroids;
Ftoci, effect of tocilizumab; Tster, time to maximal expansion with steroid therapy; Ttoci, time to maximal expansion with tocilizumab therapy.

higher exposure are more likely to have CRS and receive
tocilizumab.7,17
The impact of tocilizumab or corticosteroids on the expansion rate was explored by expanding the structural model to
include a tocilizumab and corticosteroid effect on ρ in Eq. 2
(see also Figure 1b). Here, T1 is the time of administration
for the first comedication, and T2 was the time of administration for the second comedication. F1 and F2 correspond to
the effect of each comedication on the growth rate ρ, where
F < 1 indicates a decrease in expansion rate as a result of
the comedication. The CRS treatment algorithm specifies
that tocilizumab be given first, followed by corticosteroids;
thus, for most patients, F1 = Ftoci (effect of tocilizumab) and
F2 = Fster (effect of steroids).16 However, if the patient received corticosteroids for other clinical conditions unrelated
to CRS, a corticosteroid dose could occur first. Although
some patients received multiple doses of tocilizumab and
corticosteroids, only the impact of the first dose was modeled. Because the corticosteroid administered was almost
always after tocilizumab administration (with the exception
of one patient who had an allergic reaction), an interaction
term was not included in the model.

t < T1
⎧ R0 eρt ,
⎪ R1 eF1 ⋅ρ(t−T1 ) ,
T1 ≤ t < T 2
f (t) = ⎨
F1 F2 ⋅ρ(t−T2 )
⎪ R2 e−α(t−T ) , −β(t−T ) T2 ≤ t < Tmax
max + Be
max ,
⎩ Ae
t ≥ Tmax

CPT: Pharmacometrics & Systems Pharmacology

(2)

The new constants R1 and R2 are given by R1 = R0 ⋅ eρT1
and R2 = R1 ⋅ eρ⋅F1 (T2 −T1 ).
The relationship between comedications and Cmax was
explored by including binary covariate effects on Cmax, described further below. Although either comedication could potentially impact any of the other model parameters, no other
effects were explored, as explained in the Discussion section.
Other comedications for CRS (e.g., IL-6 and TNFα antagonists) were not modeled because only 10 patients received
such drugs. The Monolix code for this model is given in the
Supplementary Material
Random-effect model. Six random effects were included
on the following parameters: Cmax, foldx, Tmax, FB, α, and β
(Table 1); all parameters were assumed to be log-normally
distributed. For the residual error model, log-transformed data
were modeled with a proportional error model (constant error
model in log-space), which is typical for the qPCR assay.18
Covariate model. Cmax was chosen as the main covariate
because it could be directly linked to area under the curve
(AUC) by integrating Eq. 1, which gives the equation below
(Supplementary Material):

AUC0−∞ = Cmax [1∕ρ + (1 − FB )∕α + FB ∕β]
This relationship indicates that intrinsic and extrinsic
factors that impact Cmax will also impact AUC. The factors
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Table 1 Model parameters
Parameter

Units

Estimate

RSE, %

Eta shrinkage

Fixed effect

fold x

—

3,900

30

—

Fixed effect

Tmax

Days

9.3

4.2

—

Fixed effect

Cmax

DNA copies/μg

24,000

20

—
—

Type

Fixed effect

Ftoci

—

1.2

7.5

Fixed effect

Fster

—

1

9

—

Fixed effect

α

1/day

0.16

11

—

Fixed effect

FB

—

0.0079

15

—

Fixed effect

β

1/day

0.0032

23

—

fold x

—

2.4

9.5

0.39

Random effect

Tmax

—

0.38

7.9

0.14

Random effect

Cmax

—

0.65

10

0.29

Random effect

α

—

0.91

8.8

0.27

Random effect

FB

—

0.8

15

0.53

Random effect

β

—

0.86

23

0.82

Residual error

a

—

0.56

3.3

—

Female (vs. male)

—

0.25

72

—

Log Cmax covariate effect

Asian (vs. white)

—

0.13

250

—

Log Cmax covariate effect

Race other/unknown
(vs. white)

—

0.33

76

—

Log Cmax covariate effect

Down syndrome

—

0.25

130

—

Log Cmax covariate effect

Received HSCT

—

0.29

62

—

Log Cmax covariate effect

No fludarabine received

—

−0.63

69

—

Log Cmax covariate effect

Study B2205J vs.
B2202

—

−0.11

190

—

Log Cmax covariate effect

Transduction efficiency

—

0.22

72

—

Log Cmax covariate effect

Dose normalized by
body weight

—

0.093

140

—

Log Cmax covariate effect

Received tocilizumab

—

0.44

59

—

—

−0.36

75

—

Random effect

Log Cmax covariate effect

Log Cmax covariate effect

Received
corticosteroids

Cmax, maximal concentration; Eta shrinkage, shrinkage of empirical Bayes estimates of the parameter; FB, fraction of transgene copies present during the
decline at the gradual rate β, starting from Tmax; fold x, fold expansion of tisagenlecleucel from baseline; Fster, effect of steroids; Ftoci, effect of tocilizumab;
HSCT, hematopoietic stem cell transplant; RSE, relative standard error of the parameter; Tmax, time to maximal expansion.
fold x is computed by the equation fold x = exp(ρ·Tmax). Eta shrinkage for each parameter is calculated by the formula (1 − var(η))/ω 2.

affecting persistence were also of interest but were not explored for reasons explained in the Discussion section.
The categorical covariates explored in this model included sex, race, Down syndrome, prior lymphodepleting
chemotherapy with fludarabine (when added to cyclophosphamide), and prior stem cell transplant. Continuous covariates included age (< 10, 10–17, ≥18 years), weight-adjusted
dose, time to first tocilizumab dose, time to first corticosteroid dose, transduction efficiency of manufactured product,
and patient weight. In some cases, there were very few patients in a particular category; therefore, this analysis should
be treated as only exploratory. It is possible that differences
in Cmax may be related to other factors, such as differences
in CD19 antigen density or variation in the capacity of a patient’s autologous T cells to proliferate, although such data
were not collected in these trials.
The covariates were explored by bootstrapping the full covariate model, where the data set was resampled and the full
model refit 500 times.19 In this analysis, the covariate analysis is done only for exploratory purposes and not to impact
dose selection. Therefore, the full model is selected as the
final model in this analysis. Further details on the motivation

for choosing the covariates and how the covariate analysis
was performed are provided in the Supplementary Material.
Analysis. The Monolix software system (Lixoft, Antony,
France) was used to estimate population parameters using
the CENSSORING column to denote data below the limit
of quantitation. Below the limit of quantitation assessments
were treated as fixed-
point censored data. A simulated
data set is provided in Data set S1 and the mlxtran code
used for fitting the model is provided in the Supplementary
Material. The technical computing packages R and Matlab
were used for some exploratory analysis, model building,
and reporting the final results.
RESULTS
Analytical model of tisagenlecleucel cellular kinetics
The base model was applied to a patient cohort (n = 90)
that included pediatric and young adult patients with r/r
B-ALL who were treated with a single dose of tisagenlecleucel. There were 836 measurements with 43 below the
limit of quantification. Patient characteristics are shown
in Table 2. The base model characterized the data well,
www.psp-journal.com
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Table 2 Patient characteristics
Patients (N = 90)

Characteristic
Sex, male/female, %

50/50

Age, median (range), years

12 (3–25)

Weight, median (range), kg

39 (14–140)

Race, %
White

the first dose of tocilizumab was given only a few days before Cmax had been achieved; therefore, in some cases, the
true impact of tocilizumab on expansion may be difficult to
assess. Although most patients receive tocilizumab prior to
corticosteroids, as specified by the CRS treatment protocol,
one patient (patient EE in Figure 4) received corticosteroids
first as the result of an allergic reaction.16

77

Asian

9

Other/unknown

14

Down syndrome, %

8

Previous stem cell transplant, %

57

Lymphodepleting chemotherapy with
fludarabine, %

94

Weight-adjusted dose of tisagenlecleucel, median (range), cells/kg

3.1 × 10 6 (0.2–5.4 × 10 6)

Total dose of tisagenlecleucel,
median (range), cells

1.0 × 108 (0.03–2.6 × 108)

Transduction efficiency, median
(range), %

19 (2.3–56)

Tisagenlecleucel cell viability, median
(range), %

94 (55–99)

Received steroids, %
Timing of first steroid dose, median
(range), days
Received tocilizumab, %
Timing of first tocilizumab dose,
median (range), days

26
7.5 (0.11–170)
36
5.7 (1–27)

as shown by the visual predictive check and individual
fits in Figure 3, with additional diagnostics included in
the Supplementary Material. The model parameters are
summarized in Table 1. The initial doubling time (ln 2/ρ)
was 0.78 days, the half-life for the initial rate of decline
(ln 2/α) was 4.3 days, and the terminal half-life (ln 2/β) was
220 days. Because the longest follow-up for this analysis
was only 1 year (Figure 3a), this terminal half-life estimate
must be interpreted with caution and will be updated as
more data become available.
Because rich sampling was collected in all patients, the
Cmax and AUC from days 0–28 could be directly computed
for most patients in this study by noncompartmental analy
sis (NCA). Good correlation between the NCA estimates
and the model-computed NCA parameters was observed
(Supplementary Material).
Impact of tocilizumab/corticosteroids on
tisagenlecleucel expansion
The impact of tocilizumab and corticosteroids on the expansion rate constant is summarized in Table 1, which shows that
Ftoci and Fster were both close to 1. Thus, neither was found
to impact the rate of expansion. This can also be observed
in Figure 4, which shows the individual fits for all patients
who had rich qPCR data (≥ 6 data points in first 2 weeks) and
who received their first tocilizumab dose on or before day
6. The rates of expansion (slope of qPCR curve) before and
after tocilizumab or corticosteroids appear similar, suggesting that treatment with tocilizumab or corticosteroids may
not impact the rate of tisagenlecleucel expansion. It should
be noted that in some patients (e.g., patient BB in Figure 4),
CPT: Pharmacometrics & Systems Pharmacology

Covariate analysis
Exploratory plots were used to screen all covariates
(Supplementary Material), and the results from bootstrapping the full covariate model showed no statistically
significant impact of any covariate on the maximal concentration of tisagenlecleucel (Table 1). Because no covariates
had a statistically significant impact on the cellular kinetic
parameters of tisagenlecleucel expansion, we concluded
that the final cellular kinetic model was the same as the
base model. Mueller and colleagues7 demonstrated that
a larger preinfusion tumor burden was associated with increased tisagenlecleucel expansion; however, preinfusion
tumor burden after lymphodepletion was not measured in
these studies.
Although the administration of tocilizumab or corticosteroids did not appear to impact the rate of expansion, we
explored the possibility of a correlation between comedication treatment and Cmax because patients with greater
peak transgene levels were more likely to have grade 3 or 4
CRS and were therefore more likely to receive comedication
treatment. The model-estimated Cmax was twofold higher in
patients who required tocilizumab and was similar to that in
the previously published NCA.7
DISCUSSION
Classical pharmacological agents, such as small molecules or monoclonal antibodies, can be described using
standard compartmental approaches to estimate the PK
parameters. The distribution, metabolism, and excretion
of small molecules and monoclonal antibodies are largely
driven by the biophysical properties of the molecule and
the plasma concentrations that result after absorption.
However, the kinetics of cell-based therapies are more
complex and are influenced by the physiological functions of the targeted cell type and by cell-extrinsic factors, such as the abundance of the CAR target molecule
in vivo. The major differences between the CAR-T cellular
kinetic model and a traditional PK model are summarized
in Table 3 and listed below. 20,21
Applicability of standard PK parameters
Unlike a traditional drug, CAR-T cells have the capacity to
proliferate. For this reason, traditional PK parameters such
as clearance and volume of distribution are not applicable
and were not computed as part of the NCA.7
Mechanism of biphasic decline
For a typical drug, the α and β slopes arise from the interplay of two processes, distribution of the drug from the
blood to peripheral tissues and elimination of the drug from
the body. However, elimination of T cells from the body is
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Figure 3 Model fits. (a) Visual predictive check of the model simulation compared with the data. The blue dots show the transgene
copies per μg of genomic DNA, and the red asterisks denote simulated data points for the measurements that were below the limit of
quantification (BLQ) of 50 transgene copies per μg. The blue lines show the 10th, 50th, and 90th percentiles calculated directly from
the population data; the blue-shaded areas denote the confidence intervals of the 10th and 90th percentiles from the model; and the
pink shaded area shows the 50th percentile. The empirical percentiles lie within the confidence intervals, except at day 5, indicating
that overall the model describes the data well. (b) Individual fits for tisagenlecleucel transgene copies per μg of genomic DNA (y-a xis)
over time in months from CAR-T cell infusion (x-a xis) observed in a representative set of patients. CAR, chimeric antigen receptor
qPCR, quantitative polymerase chain reaction.
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Figure 4 Individual fits for a subset of all patients with rich quantitative polymerase chain reaction (qPCR) sampling who received
tocilizumab and/or corticosteroids. The red dashed lines indicate treatment with corticosteroids, and the green lines indicate treatment
with tocilizumab. Each dot represents a measurable qPCR value. Black horizontal lines indicate the limit of quantification equal to 50
transgene copies per μg of genomic DNA. BLQ, below the limit of quantification.

Table 3 Difference between kinetics of a small-molecule oral dose and CAR-T cell therapy
Property
Ability to proliferate
Reason for α and β phase
Terminal half-life time scale

Small molecule

CAR-T cell17,24

No

Yes

Distribution and elimination

Contraction and persistence

Hours, days, or weeks

Years

Applicability of traditional NCA parameters
(clearance and volume of distribution)

Applicable

Not applicable because of the ability of CAR-T cells
to proliferate

Variability in product from patient to patient

None

Variability exists because of variability in patient
immune systems

Yes, although it may be nonlinear

No relationship between dose and exposure
detected
{
R0 eρt ,
t < Tmax
f (t) =
Ae−α(t−Tmax ) + Be−β(t−Tmax ) , t ≥ Tmax

Clear relationship between dose and
exposure
Kinetic equation following small-molecule
oral dose or intravenous CAR-T cell dose
Sign of exponent for initial increase after
dosing

A·exp(−αt) + B·exp(−βt) − (A + B)·exp(−kat)
Negative (−ka)

CAR, chimeric antigen receptor; NCA, noncompartmental analysis; Tmax, time to maximal expansion.
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Positive (+ρ)
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governed by fundamentally different mechanisms. The α
slope corresponds to a rapid contraction because of the
programmed apoptosis of most activated lymphocytes
following the initial immune response, and the β slope corresponds to a gradual decline of memory cells, which can
persist in the body for years or even decades.13,14 Although
the persistence phase of tisagenlecleucel has kinetics similar to that of long-term memory cells, it may also be that the
persistence is the result of the continual production of B cell
precursors expressing CD19, with the surrogate antigen acting as an endogenous vaccine. In this respect, the long persistence of CD19 CAR-T cells may be similar to T cells that
are specific for latent viruses such as cytomegalovirus.22
The model presented in Figure 2 is not the only semimechanistic model that gives rise to exponential growth
followed by biexponential decay in Eq. 1. If memory cells
were produced during the expansion phase as well or if cells
could transition back and forth from the effector to memory states, then the analytic solution to such a model would
have the same functional form. It is also possible that the
terminal phase is not a result of the formation of memory
cells but rather the low level of constant proliferation in response to the continual production of the CD19 antigen; the
kinetics of this process would also look similar. DeBoer and
Perelson4 also showed in equations 8–10 of their paper that
rather than have expansion stop at Tmax, one could use a
“cascade” model of cell division, modeling each generation
of expansion. Although this model is more realistic, it behaves similarly to the simpler model used here.
Distribution
Similar to a traditional drug, tisagenlecleucel has the capacity to distribute to other tissues within the body.
Lymphocytes can traffic to the bone marrow, gut, spleen,
and lymph nodes, with peripheral blood containing only 2%
of the total body lymphocyte population.19 The bone marrow
CAR-T cell population, where progenitor B cells expressing
CD19 are continually produced, may be more important
than blood for establishing relationships between the cellular kinetics of tisagenlecleucel and safety and efficacy.
Long-term persistence
In the current analysis, the longest follow-up time was approximately 1 year, thus limiting the accuracy of the estimate
for the terminal half-life. For this reason, a covariate analysis
of the terminal half-life was not performed. However, longer persistence for CAR-T cells has been observed.7 Two
of the first three patients treated with tisagenlecleucel in
2010 currently maintain low but stable levels of CAR-T cells
and have B cell aplasia now, 8 years later. In patients with
HIV treated with CD4ζ CAR-T cells, the average half-life of
the CAR-T cell in peripheral circulation has been reported
to be 17–23 years.15 As tisagenlecleucel-treated patients
remain in follow-up in these trials, this analysis will be updated such that a better estimate of the terminal half-life
can be obtained.
Model equations
Because CAR-T cells have the capacity to proliferate beyond
the initial dose infused and the mechanism of elimination is

different than that of traditional drugs, it is necessary to use
a different structural model to describe the cellular kinetics than the standard compartmental models used for the
population PK of traditional drugs. Although the profile in
Figure 1a may look similar to a standard two-compartment
PK model describing oral absorption of a small molecule,
the kinetics of tisagenlecleucel is driven by fundamentally
different processes that require different mathematical
equations to model expansion and persistence. In particular, the cellular kinetic model describes the exponential
expansion of the tisagenlecleucel transgene levels with
positive exponent ρ. This contrasts with the standard two-
compartment model with oral absorption, where all exponents are negative, as shown in the analytical solution in
Table 3.
No relationship between dose and exposure
Unlike a traditional drug, no relationship was detected between tisagenlecleucel dose and Cmax or any other model
parameter (Supplementary Figure S2a). Although a dose-
exposure relationship is generally expected for most drugs,
the lack of a relationship here may be a result of the capacity of tisagenlecleucel to proliferate in vivo and heterogeneity across a patient’s product, native immune system, and
tumor burden.
Differences between CAR-T kinetics and traditional
immune kinetics
Unlike in natural immune responses, where thymic output
contributes new cells into the peripheral compartment,5
there is no de novo generation of CAR-T cells. However,
there is de novo generation of the CD19+ antigen, so it is not
clear if the persistent cells are true memory cells or if they
continually proliferate at a low rate in response to antigen.
Effect of tocilizumab and corticosteroids on
expansion
A twofold higher Cmax was observed in patients that received tocilizumab. This is thought to be because patients
with greater expansion are more likely to develop grades
3 and 4 CRS and are therefore more likely to require tocilizumab therapy. An impact of tocilizumab therapy on the
rate of expansion was not detected. As shown in Figure 4,
individual fits of patient data showed no changes in the rate
of expansion of tisagenlecleucel before and after the administration of tocilizumab, and some patients had a ≥ 10-
fold increase in tisagenlecleucel levels even after receiving
their first dose of tocilizumab for CRS. Given this observation, no further analysis was performed on patients who
received a second dose of tocilizumab. These data suggest
that greater tisagenlecleucel expansion (Cmax) leads to an
increased likelihood of CRS, and therefore, a correlation exists between tocilizumab administration and exposure.7,17
However, it is important to note that these analyses did not
examine the impact of the prophylactic use of tocilizumab
to treat CRS on Cmax; assessing prophylactic tocilizumab
would need to be done in a carefully controlled clinical trial.
Although the analyses presented herein demonstrate
that corticosteroids and tocilizumab did not impact the
Cmax, it is important to recognize that corticosteroids were
www.psp-journal.com
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administered at low doses during a short duration and that
the patients were weaned rapidly. The CRS treatment algorithm used in ELIANA and ENSIGN specified that corticosteroids be given only when the first dose of tocilizumab did not
lead to an improvement in CRS. Furthermore, methylprednisolone doses were ≤ 2 mg/kg per day. Thus, the effects
of giving corticosteroids at higher doses before tocilizumab,
without tocilizumab, or before the development of severe
CRS were not assessed.
None of the other covariates explored (including corticosteroid dosing) were confirmed to have an effect on Cmax.
Although it has been observed elsewhere that baseline
tumor burden also correlates with an increased expansion,23
this was not assessed because in the ELIANA and ENSIGN
trials, bone marrow biopsies were not collected after lymphodepletion but before tisagenlecleucel dosing.
This work represents the first mixed-effect model-based
analysis of a CAR-T cell therapy and may have broad application to multiple CAR treatment platforms. Our cellular
kinetic model may be adapted to characterize the expansion
and persistence of genetically modified cells across multiple
disease indications, within various cell types, and between
different costimulatory domains. A fundamentally different
model structure was needed to describe these data than
is used for standard population cellular kinetic models because CAR-T cells can proliferate exponentially and expand
> 1,000-fold in most patients. The model consistently described aggregate data and individual patient data, and the
cellular kinetic analysis provided similar results to those in the
previous NCA.7 Patients with higher peak transgene levels
were more likely to receive tocilizumab, consistent with prior
results, on the basis of NCA.24 Finally, no effect of tocilizumab
and corticosteroids on the rate of expansion was observed.
Supporting Information. Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology
website (www.psp-journal.com).
Supplementary Material S1. Contains exploratory plots, diagnostics,
derivations, and the mlxtran model file.
Data set S1. Simulated dataset based on the model that works with the
mlxtran model file in Supplementary Material S1.
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